Aptose to Present at September 2021 Investor Conferences


2021-08-31 22:30:12 BioSpace


SAN DIEGO and TORONTO, Aug. 30, 2021 -- Aptose Biosciences Inc. , a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate at the upcoming conferences in September 2021: The webcasts also can be accessed through the Aptose website at www.aptose.com and will be archived shortly after the live events. About Aptose Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: luxeptinib, an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1a/b trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and is in a separate Phase 1a/b trial in patients with relapsed or refractory acute myeloid leukemia (AML); APTO-253, the only known clinical stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS). For further information, please contact:
圣地亚哥和多伦多,2021年8月30日--Aptose Biosciences Inc.是一家开发针对癌症潜在机制的高度差异化治疗的临床阶段公司,今天宣布Aptose管理团队将参加2021年9月即将举行的会议: 网播也可通过Aptose网站www.Aptose.com,并将在现场活动结束后不久存档。 关于Aptose Aptose Biosciences是一家临床阶段的生物技术公司,致力于开发个性化疗法,解决肿瘤学中未满足的医疗需求,最初专注于血液学。该公司的小分子癌症治疗管道包括旨在提供单一药物疗效和增强其他抗癌治疗和方案的疗效而不产生重叠毒性的产品。该公司有两个针对血液系统恶性肿瘤的临床阶段研究产品:卢森堡替尼,一种口服的、第一类突变不可知的FLT3/BTK激酶抑制剂,在复发或难治性B细胞恶性肿瘤患者中处于1a/B阶段试验,包括慢性淋巴细胞白血病(CLL)、小淋巴细胞淋巴瘤(SLL)和非霍奇金淋巴瘤(NHL),这些患者对标准治疗失败或不耐受,并在复发或难治性急性髓细胞白血病(AML)患者中处于单独的1a/B阶段试验;APTO-253是目前唯一已知的直接靶向MYC癌基因并抑制其表达的临床分期药物,正处于治疗复发或难治性AML或高危骨髓增生异常综合征(MDS)患者的1a/B期临床试验中。 如需进一步资料,请联络: